These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32896865)

  • 1. Immunology of tissue homeostasis, ovarian cancer growth and regression, and long lasting cancer immune prophylaxis - review of literature.
    Bukovsky A
    Histol Histopathol; 2021 Jan; 36(1):31-46. PubMed ID: 32896865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with B7H3-redirected bispecific antibody and Sorafenib elicits enhanced synergistic antitumor efficacy.
    Huang C; Li H; Feng Y; Li X; Zhang Z; Jiang C; Wang J; Yang C; Fu Y; Mu M; Zhao S; Wang Z; Kuang Y; Hou H; Wang Y; Guo W; Xu J; Yang H; Zhou L; Tong A; Guo G
    Theranostics; 2020; 10(23):10498-10512. PubMed ID: 32929362
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer.
    Capellero S; Erriquez J; Melano C; Mesiano G; Genta S; Pisacane A; Mittica G; Ghisoni E; Olivero M; Di Renzo MF; Aglietta M; Sangiolo D; Valabrega G
    Sci Rep; 2020 Apr; 10(1):6478. PubMed ID: 32296104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses
    Flores I; Hevia D; Tittarelli A; Soto D; Rojas-Sepúlveda D; Pereda C; Tempio F; Fuentes C; Falcón-Beas C; Gatica J; Falcón-Beas F; Galindo M; Salazar-Onfray F; González FE; López MN
    J Immunol Res; 2019; 2019():9631515. PubMed ID: 31886313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basics of immunotherapy for epithelial ovarian cancer.
    Bund V; Azaïs H; Bibi-Triki S; Lecointre L; Betrian SB; Angeles MA; Eberst L; Faller E; Boisramé T; Bendifallah S; Akladios C; Deluche É;
    J Gynecol Obstet Hum Reprod; 2022 Feb; 51(2):102283. PubMed ID: 34875397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunology and ovarian cancers.
    Lee WL; Wang PH
    J Chin Med Assoc; 2020 May; 83(5):425-432. PubMed ID: 32149893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer.
    Banville AC; Wouters MCA; Oberg AL; Goergen KM; Maurer MJ; Milne K; Ashkani J; Field E; Ghesquiere C; Jones SJM; Block MS; Nelson BH
    Gynecol Oncol; 2021 Feb; 160(2):520-529. PubMed ID: 33342620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting cytokines secreted by CD4
    Ke X; Shen L
    Scand J Immunol; 2019 Feb; 89(2):e12736. PubMed ID: 30485902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
    Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
    Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
    Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer.
    Pereira M; Matuszewska K; Jamieson C; Petrik J
    Front Endocrinol (Lausanne); 2021; 12():772349. PubMed ID: 34867818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
    Høgdall E; Høgdall C; Vo T; Zhou W; Huang L; Marton M; Keefe SM; Busch-Sørensen M; Sørensen SM; Georgsen J; Mejlgaard E; Nedergaard L; Steiniche T
    Int J Gynecol Cancer; 2020 Jul; 30(7):1034-1042. PubMed ID: 32527769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
    Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
    J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment for recurrent epithelial ovarian cancer.
    Li YT; Liu CH; Wang PH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):803-804. PubMed ID: 34507651
    [No Abstract]   [Full Text] [Related]  

  • 17. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
    Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
    J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding dendritic cell immunotherapy in ovarian cancer.
    Drakes ML; Stiff PJ
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Brewer M; Angioli R; Scambia G; Lorusso D; Terranova C; Panici PB; Raspagliesi F; Scollo P; Plotti F; Ferrandina G; Salutari V; Ricci C; Braly P; Holloway R; Method M; Madiyalakan M; Bayever E; Nicodemus C
    Gynecol Oncol; 2020 Mar; 156(3):523-529. PubMed ID: 31916979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as a treatment for recurrent epithelial ovarian cancer-National Cancer Institute experience.
    Fahim MI; Nassar OA; Mansour OM; Ali AM; Mahmoud AM; Allam RM; Kamal A
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):139-141. PubMed ID: 30470604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.